Clinical Trial

Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes

BMF-219 is a novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 1…

1 year ago

MediOrbisTM Partners with INTERVENT International to Offer Proven Health Risk Management, Longitudinal Care and Medical Weight Loss Services

CLEVELAND, OH / ACCESSWIRE / October 4, 2023 / MediOrbis, a global multi-specialty telehealth company with comprehensive specialty telemedicine services…

1 year ago

AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance

 Fiscal Year 2024 First Quarter Highlights Net sales of $78.7 million as reported Includes $0.7 million of Dialysis and BioSentry…

1 year ago

FloraWorks Appoints Cannabis Scientist Dr. Mike McCormick as VP of Strategy

Portland, Oregon--(Newsfile Corp. - October 4, 2023) - FloraWorks Holdings Inc., a leading cannabinoid therapeutics company, announced the appointment of Dr.…

1 year ago

FSD Pharma Wins $2.8 Million Dollar Award Plus Accruing Interest from Dr. Raza Bokhari; Set Aside Motion Brought by Bokhari, Now CEO of Medicus Pharma, Dismissed by the Ontario Superior Court of Justice

TORONTO, ON / ACCESSWIRE / October 4, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…

1 year ago

Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company’s Combination Vaccine Against Influenza and COVID-19

mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccinesCompany…

1 year ago

BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT™ in Advanced Breast Cancer

PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)…

1 year ago

Tryp Therapeutics Announces Private Placement of Unsecured Convertible Debentures for Gross Proceeds of up to AUD$175,000

KELOWNA, BC / ACCESSWIRE / October 4, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP) announces that, further…

1 year ago

Hemostemix Closed $320,125 Private Placement

Calgary, Alberta--(Newsfile Corp. - October 3, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce…

1 year ago